Beverly Hills 12/2/2009 8:41:04 AM
News / Business

FDA Approval for Dyax’s Genetic Disorder Drug, Kalbitor

Finance World News Update by EQUITIES Magazine

The Food and Drug Administration approved Dyax Corp’s Kalbitor for the treatment of the genetic disorder hereditary angioedema in patients sixteen and over. The drug is the first injectable treatment approved for the disorder in the U.S.

 

Characterized by the accumulation of fluids outside of the blood vessels, the rare disorder causes swelling in extremities, the intestinal tract or airways.

 

Dyax stock jumped in after-hours trading, up $1.33 or 38 percent.

 

About EQUITIES:

Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.

 

Sign up for a free one-year subscription to EQUITIES Magazine